Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 9023347.
- Also identified by PMC identifier 19604.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The switch from a quiescent tumor to an invasive tumor is accompanied by the acquisition of angiogenic properties. This phenotypic change likely requires a change in the balance of angiogenic stimulators and angiogenic inhibitors. The nature of the angiogenic switch is not known. Here, we show that introduction of activated H-ras into immortalized endothelial cells is capable of activating the angiogenic switch. Angiogenic switching is accompanied by up-regulation of vascular endothelial growth factor and matrix metalloproteinase (MMP) bioactivity and downregulation of tissue inhibitor of MMP. Furthermore, we show that inhibition of phosphatidylinositol-3-kinase leads to partial inhibition of tumor angiogenesis, thus demonstrating that activated H-ras activates tumor angiogenesis through two distinct pathways. Finally, we show evidence for two forms of tumor dormancy.
Medical subject headings
- Antigens, Polyomavirus Transforming
- Neoplasms, Experimental
- Neovascularization, Pathologic
- Oncogene Protein p21(ras)
- Oncogenes